Learn More About Benefits of
Becoming a Sponsor!
Industry
Increased Awareness & Networking
- Improve Patient & Physician Awareness through uploaded Sponsor-controlled Educational Content, Trial Criteria, Presentations & Publications,all related to your investigational product.
- Market Globallyon a highly visible platform to a highly focused audience including cancer patients who can greatly benefit enrolling on yout trial.
- Network on a Single Platformand align with a Multitude
of Professionals from several areas of the Theranostic Industry
including:
-
Sponsors
-
CROs
-
CDMOs
-
Couriers
-
Advocacy Groups
-
Venture Capitalists
-
Medical Societies
-
Physicians
-
- Promote Upcoming Theranostic Conferences
- Access to Real-time Trial Stats & Site Stats
Collaborations
Advancing the field of cancer Theranostics requires a multitude of industries working together. Companies provide discovery, development, production, clinical trial management, radioactive courier services, equipment suppliers, staffing, dosimetry, capital investment, regulatory agencies, cancer centers, and many more.
About Us
TheranosticTrials was developed through the collaboration of 2 key opinion leaders in the field of Radiopharmaceuticals. Drs. Luke Nordquist and Oliver Sartor saw the need for a such a web-based tool to provide patient education & ultimately improve access to the rapidly expanding field of radiopharmaceutical clinical trials. Patients globally are seeking access to these highly sought-after clinical trials which are providing new hope.
Distinguished Investigator
A Distinguished Investigator of Theranostics is a level of distinction conferred upon an individual physician who has demonstrated a mastery of conducting novel radioligand therapies and molecular imaging clinical trials.
Professor Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD, FMedSci
Professor Johann de Bono is Regius Professor of Cancer Research at The Institute of Cancer Research and honorary consultant in medical oncology at The Royal Marsden Hospital. He led on the development of abiraterone, cabazitaxel, enzalutamide, olaparib, lutetium PSMA and the molecular genomic stratification and germline sequencing of advanced prostate cancer. Professor de Bono leads the Drug Development Unit at the Royal Marsden which comprises >100 staff and conducts >50 Phase I clinical trials at any one time and runs a research laboratory. He has been involved in developing more than 200 new agents and is currently evaluating many new drugs in early clinical trials. He has published >600 papers and has mentored many PhD students.
Read MoreConferences
EANM 2024
EANM is a place to discuss the latest theranostic advances, the most impactful clinical evidence, the most recently developed radiopharmaceuticals, and the most novel imaging and detection technologies. The program focus specifically on facilitating interactions and exchanges across disciplines, competences, and generations.Metals in Medicine
The Metals in Medicine GRC is a premier, international scientific conference focused on advancing the frontiers of science through the presentation of cutting-edge and unpublished research, prioritizing time for discussion after each talk and fostering informal interactions among scientists of all career stages. The conference program includes a diverse range of speakers and discussion leaders from institutions and organizations worldwide, concentrating on the latest developments in the field.19th International Conference on Radiopharmaceutical Therapy (ICRT)
The Symposium will bring together Nuclear Medicine leaders, physicians, scientists, healthcare professionals, and others interested in the challenges and advancements related to nuclear medicine and molecular imaging and therapy.21st European Symposium on Radiopharmacy & Radiopharmaceuticals
Hosted by the Institute for Nuclear Sciences Applied to Health (ICNAS), the 21st European Symposium on Radiopharmacy and Radiopharmaceuticals will feature a combination of high-level scientific lectures, back-to-basics educational sessions and fruitful discussions, together with nice social events will make the 21st edition of ESRR successful, continuing its long-standing tradition of excellence.SNMMI Therapeutics Conference Fall 2024
This exciting event will bring together leaders in radiopharmaceutical therapy to explore the latest innovations and advancements in the field. This conference is a must-attend if you want to expand your knowledge and stay up to date on the latest developments in the field. With two-and-a-half days of informative sessions and networking opportunities, you'll have the chance to connect with colleagues, enhance your knowledge, learn from experts, and gain invaluable insights.ESMO Congress 2024
A comprehensive educational and scientific conference that will foster exchange and debate of translational cancer science, showcase first announcements of potentially practice changing data and stimulate multidisciplinary discussions to improve treatment options for our patients.ICPO Virtual Theranostics Summit 2024
World-class scientific program with invited experts from academia and industry in the field of theranostics in precision oncology.6th Annual TRP
Gathering world-class speakers to address the most exciting opportunities and challenges spanning novel targeting mechanisms, alpha vs beta emitters, nuclear medicine clinical expertise, isotope supply, European logistics chains as well as pricing and reimbursement- don’t miss the biggest edition of the 6th Targeted Radiopharmaceuticals Summit to date!ICRIIC '24
The International Conference on Radiology, Imaging and Immunotherapy in Cancer (ICRIIC), hosted by Research Leagues, serves as a premier global platform for sharing the latest advancements and developments in these fields. The goal is to provide a competitive forum for practitioners and researchers from both industry and academia to come together and discuss cutting-edge advances.International Conference on Radiopharmacy and Radiopharmaceuticals (ICRR)
Today more than ever before it is extremely important to stay abreast of the changing landscapes of the Pharmacological and Pharmaceutical Sciences world. The multidisciplinary focus of this event aims to bring together presenters and attendees from different fields with expertise in various areas of Pharmacological and Pharmaceutical Sciences, providing an excellent opportunity to participate in the international exchange of ideas, current strategies, concepts and best practices, collaborations, and cooperation, offering a broader perspective and more enriching experience. The program includes time allocated for networking, peer-to-peer discussions, and exploring the host city.CANM '24
CANM is a key platform offering top-tier educational and networking opportunities for the nuclear medicine and molecular imaging community. The Canadian Association of Nuclear Medicine tirelessly works towards promoting excellence in nuclear medicine practice, fostering professional competence, setting clinical guidelines, and encouraging research. We're committed to ensuring Canadians receive the highest quality nuclear medicine services.Radionuclide Theranostics for the Management of Cancer
The Radionuclide Theranostics for the Management of Cancer GRC is a premier, international scientific conference focused on advancing the frontiers of science through the presentation of cutting-edge and unpublished research, prioritizing time for discussion after each talk and fostering informal interactions among scientists of all career stages. The conference program includes a diverse range of speakers and discussion leaders from institutions and organizations worldwide, concentrating on the latest developments in the field.11th Balkan Congress of Nuclear Medicine
The 11th Balkan Congress of Nuclear Medicine is organized by the Macedonian Association of Nuclear Medicine in collaboration with the Balkan Societies of Nuclear Medicine. The event will host nuclear medicine professionals as well as colleagues from other specialties tightly connected to the field of nuclear medicine with it’s diagnostic and therapeutic possibilities. The scientific program will cover the most recent advances and practices in the fields of molecular imaging and therapy with radionuclides.RLT Components
RADIOLIGAND THERAPY (RLT) is a highly effective approach to very accurately locating cancer cells and effectively killing those same cells by delivery various radioisotopes to a specific target that is located on a type of cancer. Some of the Radioisotopes are diagnostic for locating cancers & some therapeutic to treat the cancers.
There are several Components to a RLT that are simply demonstrated in the truck diagram including:
- Cancer Targets
- Ligand (demonstrated as the Truck GPS set to find a specific Target)
- Diagnostic Radioisotopes (demonstrated as light bulbs that light the cancer Targets on a PET scan)
- Therapeutic Radioisotopes (demonstrated as bombs that kill cancer cells that express the target with either Alpha or Beta radiation)
- Linker (demonstrated as the hitch keeping the Radioisotope attached to the Ligand)
- Chelator (demonstrated as the Trailers which keeps the Radioisotope on Target).
To learn more about the specific components being studied today on clinical trials around the world check out the RLT COMPONENTSTab.
Education
Stats
Sponsors
.svg)
© 2021 XCancer Software LLC
Contact XCancer: 402-991-8468